Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its position in Verve Therapeutics, Inc. (NASDAQ:VERV) by 465.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 42,781 shares of the company’s stock after purchasing an additional 35,214 shares during the period. Nisa Investment Advisors LLC owned 0.05% of Verve Therapeutics worth $241,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of VERV. Barclays PLC increased its holdings in shares of Verve Therapeutics by 139.8% in the 3rd quarter. Barclays PLC now owns 222,919 shares of the company’s stock valued at $1,079,000 after acquiring an additional 129,944 shares during the last quarter. State Street Corp raised its holdings in shares of Verve Therapeutics by 27.0% during the third quarter. State Street Corp now owns 4,253,217 shares of the company’s stock worth $20,586,000 after purchasing an additional 903,809 shares during the period. Braidwell LP bought a new position in shares of Verve Therapeutics in the 3rd quarter worth about $3,020,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Verve Therapeutics by 28.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 572,173 shares of the company’s stock valued at $2,769,000 after buying an additional 126,110 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Verve Therapeutics during the 3rd quarter valued at about $500,000. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Trading Up 6.2 %

VERV opened at $7.70 on Thursday. The business’s 50 day moving average is $6.13 and its 200-day moving average is $5.84. The stock has a market cap of $651.88 million, a PE ratio of -3.13 and a beta of 1.68. Verve Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last announced its earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.11. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm had revenue of $6.87 million for the quarter, compared to the consensus estimate of $2.75 million. During the same quarter in the previous year, the business earned ($0.72) EPS. The firm’s revenue for the quarter was up 120.2% on a year-over-year basis. As a group, analysts forecast that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on VERV. Royal Bank of Canada cut their target price on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. HC Wainwright reduced their price objective on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group increased their target price on Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.